A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)

Inclusion Criteria: * Fertile female aged between 20 and 49 * Subjects who are infected with HPV 16 type only or with HPV 16 type and any other types listed below 1\) low risk type of HPV, 2) HPV 16-related type * Subjects who are diagnosed as Cervical interaepithelial neoplasia 2/3 (CIN2/3) by colposcopic biopsy within 6 weeks before enrollment * All lesions must be observable by colposcopy and CIN2 or higher lesion must be less than 1/2 in the transformation zone area * Willing to use adequate contraception methods during the study period * Eligible based on screening test results * Normal electrocardiogram * Voluntarily signed informed consent form Exclusion Criteria: * Subjects who are diagnosed with Carcinoma In Situ with microinvasion or suspicious invation * Presence of adenocarcinoma or glandular lesion in the cervix * Subjects who are infected with HPV type 18-related type * Subjects with autoimmune disease * Current or prior treatment past 2 months with immunosuppressant therapies * Hypersensitive to the investigational drug * Subjects who currently have acute diseases that require medical attention * Participation in other studies involving investigational drug(s) or investigational device(s) within 3 months * Currently having chronic pancreatitis or diagnosed with acute pancreatitis * Currently having underlying diseases including inflammatory intestinal diseases and tumors, ulcer, bleeding or puncture in the gastrointestinal tract * Pregnant or breastfeeding * Subjects with active or inactive hepatitis, or infectious disease * History of HIV infection * History of therapeutic HPV vaccination * Subjects who require continuous use of antibiotics * Administration of blood product within 3 months before signing informed consent form * History of vaccination within 2 months before signing informed consent form (4 months in case of live vaccine)